The clinical value of sarcopenia in predicting the efficacy of bronchial artery chemoembolization in patients with lung cancer
10.3969/j.issn.1008-794X.2025.09.007
- VernacularTitle:肌少症对肺癌患者支气管动脉化疗栓塞疗效的预测作用
- Author:
Jinying WU
1
;
Linqiang LAI
;
Jialu ZHAO
;
Suhang CHEN
;
Jianfei TU
Author Information
1. 323000 浙江丽水 温州医科大学丽水医院(丽水市人民医院)放射科
- Keywords:
lung cancer;
sarcopenia;
bronchial artery chemoembolization
- From:
Journal of Interventional Radiology
2025;34(9):950-956
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of sarcopenia in predicting the efficacy of bronchial artery chemoembolization(BACE)in patients with lung cancer.Methods The clinical data of 160 patients with lung cancer,who received BACE treatment at the Lishui Municipal Central Hospital of China from December 2012 to August 2021,were retrospectively analyzed.Using CT images to measure and calculate the skeletal muscle index(SMI)at the 4th thoracic vertebra(T4)level,patients with T4-SMI below the gender specific quartile were classified in sarcopenia group(n=40),and patients with T4-SMI above the threshold were classified in non-sarcopenia group(n=120).Kaplan-Meier method was used to compare the differences in progression-free survival(PFS)and overall survival(OS)between the two groups after BACE treatment,and Cox regression analysis was used to determine the risk factors affecting prognosis.Results In the non-sarcopenia group and the sarcopenia group,the median PFS was 5.6 months and 3.0 months respectively(x2=5.141,P=0.023),and the postoperative 14-month PFS rates were 16.7％and 5.0％respectively.There was no statistically significant difference in OS between the two groups(P＞0.05).Cox multivariate analysis showed that sarcopenia(HR=1.557,95％CI=1.083-2.238,P=0.017)was an independent risk factor for postoperative PFS after BACE.Conclusion Sarcopenia is an independent risk factor affecting the efficacy of BACE in patients with lung cancer,and sarcopenia can be used as a predictive indicator for the postoperative efficacy of BACE.
